Perfusion Index may Predict for SAIH in Orthopedic Surgery, Less Effective in Elderly: Study

A new study published in the journal of BMC Surgery showed that Perfusion Index (PI) is a non-invasive tool for predicting spinal anesthesia-induced hypotension in lower extremity orthopedic surgery patients (cut-off value = 2.25), but shows reduced accuracy in elderly individuals.

The most frequent side effect of spinal anesthetic is hypotension, which is becoming more widespread and potentially harmful in elderly people. Thus, this study was set to examine how the PI predicts spinal anesthesia-induced hypotension (SAIH) during lower extremity orthopedic surgery, as well as how age affects this prediction.

This research was performed on 120 elective patients aged 18 and older who were in the ASA I-II-III risk categories and were receiving supine lower extremities surgery while under spinal anesthesia. Every patient’s demographics, baseline hemodynamic parameters, and PI values were evaluated and documented.

Patients were split into two groups as non-elderly (group NE, under 65) and elderly (group E, over 65). Before spinal anesthetic began, a 400 mL maximum saline infusion was started. For spinal anesthesia, 10–12.5 mg 0.5% hyperbaric bupivacaine was administered to each subject, and the block’s dermatomal distribution was recorded. Hemodynamic factors, PI readings, and any possible problems were tracked during the procedure.

There were 101 patients in the final analysis. Both groups’ demographics were comparable, with the exception of age, ASA, and operation type. A multivariable logistic regression analysis was performed to further assess the PI’s independent predictive value for SAIH, controlling for surgical variables, age, BMI, comorbidities, and ASA score.

Higher ASA values were linked to increased risk (p = 0.024), according to the research, which found that ASA score was a strong predictor of hypotension. Interestingly, it was discovered that the preoperative PI was a significant independent predictor of hypotension (p = 0.020).

In all patients, but particularly in group NE, a high baseline PI was directly associated with SAIH (AUROC = 0.675 (0.568–0.781), p = 0.002; AUROC = 0.727 (0.579–0.875), p = 0.006).

SAIH was not predicted by baseline PI in group E (AUROC = 0.579 (0.417–0.740), p = 0.336). In group NE, the PI cut-off was 1.75 (68% sensitivity, 64% specificity), whereas in all patients, a cut-off of 2.25 indicated SAIH with 65% sensitivity and specificity.

Hemodynamic and PI data at various time points did not significantly differ between groups (p > 0.05). When compared to group E, group NE utilized more fluids and bupivacaine (p = 0.013 and 0.014, respectively). Above the cut-off levels, both groups had higher rates of ephedrine usage and hypotension (p > 0.05).

Overall, for patients having orthopedic lower extremity surgery, PI is regarded as a non-invasive technique that may be used to predict SAIH (cut-off value = 2.25). The senior patient group, however, did not show the same efficacy.

Reference:

Kavak Akelma, F., Mafizer, M., & Nalbant, B. (2025). Perfusion index as a predictor of hypotension after spinal anesthesia in lower extremity orthopedic surgery: a prospective observational trial. BMC Surgery, 25(1), 348. https://doi.org/10.1186/s12893-025-03036-y

Powered by WPeMatico

HEPA Filters Lower Blood Pressure in High-Pollution Areas: Study

Researchers have found in a new randomized trial that using high-efficiency particulate arrestance (HEPA) filters in homes significantly reduced elevated blood pressure in individuals exposed to air pollution near major highways. However, no benefit was observed in people with normal systolic blood pressure (≤120 mm Hg). Researchers recommend targeting HEPA filtration for vulnerable populations residing in high-pollution zones. The study was published in the Journal of the American College of Cardiology by Doug B. and colleagues.

Particulate matter, and particularly PM2.5 (less than 2.5 micrometers in diameter), has been linked for decades with elevated cardiovascular risk, including hypertension. Since persons who reside near busy roads are exposed continuously to elevated levels of PM, enhancing indoor air quality may offer a focused strategy for the reduction of such risks. This pragmatic randomized crossover trial sought to determine whether HEPA filtration might be capable of providing quantitative improvements in blood pressure in such individuals.

The trial included 154 adults who lived next to highways. The participants’ average age was 41.1 years, 59.7% were female, and 68.2% were non-Hispanic White. Participants were predominantly from higher socioeconomic strata. The mean baseline brachial blood pressure was 118.8/76.5 mm Hg.

Each residence was randomized to start with either a 1-month interval of HEPA filtration or a 1-month sham (placebo) filtration. This was followed by 1 month of washout and then 1 month of the alternate filtration. Blood pressure was measured at the start and end of each phase of filtration. PM concentrations were also tracked within a subset of homes. Linear mixed models were applied to evaluate changes in BP, controlling for different individual and temporal factors.

Key Findings

  • 154 participants enrolled; mean age 41.1 years.

  • 59.7% female; 68.2% non-Hispanic White.

  • Baseline BP: 118.8/76.5 mm Hg.

  • 2.8 mm Hg reduction in SBP following HEPA filtration among individuals with SBP ≥120 mm Hg (P = 0.03).

  • 0.2 mm Hg increase in SBP following sham filtration (P = 0.85).

  • Net 3.0 mm Hg benefit of HEPA filtration compared to sham (P = 0.04).

  • No effect on diastolic BP or normotensive individuals.

  • Substantial PM reduction validated in HEPA-filtered residences.

The randomized crossover trial finds that HEPA air cleaners can produce clinically relevant reductions in systolic blood pressure in adults with high baseline levels, even where ambient air pollution is relatively low. The results validate the application of indoor air filtration as an effective and non-pharmaceutical intervention to address hypertension and cardiovascular outcomes, particularly among residents of large-traffic zones.

Reference:

Brugge, D., Eliasziw, M., Thanikachalam, M., Kuchhal, V., Morson, C., Vazquez-Dodero, T., Mertl, A., Tallam, P., Kunwar, S., Sprague Martinez, L., Rashid, H. S., Singh-Smith, K., Gates, H., Palma, S., Goldstein-Gelb, W., Ginzburg, S. L., Hersey, S. O., Majluf, F., & Zamore, W. (2025). Effect of HEPA filtration air purifiers on blood pressure: A pragmatic randomized crossover trial. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2025.06.037

Powered by WPeMatico

Oral Lesions at Occlusal Plane May Indicate Cinnamon-induced contact stomatitis, suggests study

A new retrospective study published in the journal of Oral Diseases found erythematous and/or white lesions at the occlusal plane to prompt suspicion of Cinnamon-induced contact stomatitis (CCS), which can be diagnosed through patient history and clinical presentation.

The study spanned for 15 years from 2010 to 2025, examined 74 cases of CCS and also reviewed documented instances in existing medical literature. The investigation revealed that CCS predominantly affects the lining of the mouth, especially the buccal mucosa, the inner cheek, and the sides of the tongue. Among the 74 patients, 67 experienced lesions on the buccal mucosa, while 50 had involvement of the lateral tongue.

The nature of the oral lesions varied, as 7 patients developed white plaque-like or lichenoid patches, resembling other chronic oral conditions and 26 patients presented with painful red, erosive, or ulcerative lesions. The largest group, 41 individuals, displayed a combination of whitish and red lesions, often mimicking other inflammatory oral diseases.

Also, once the patients discontinued the use of cinnamon-flavored gums or candies, all cases showed complete resolution within just one week. None of the patients experienced a recurrence, provided they avoided re-exposure to these cinnamon products.

This research reviewed previously reported cases and identified 40 well-documented examples of CCS tied to cinnamon-flavored gums, candies, and mints. In each instance, a clear temporal link between cinnamon consumption and oral lesion development was observed, supported by either clinical or histopathological images.

Overall, the findings suggest the importance of recognizing CCS as a potential cause of oral discomfort and lesions that may otherwise be mistaken for chronic inflammatory or autoimmune conditions. Dentists and clinicians are advised to consider CCS when patients present with unexplained white or red oral lesions, especially if these appear along the occlusal plane, which is the area where teeth meet during chewing. While cinnamon remains a popular flavor in gums and candies, this study highlights the need for caution among frequent consumers who develop unexplained mouth lesions. 

Source:

Kalogirou, E.-M., Aktypi-Bampouranou, A., Vasilaki, M., Chatzidimitriou, K., & Tosios, K. I. (2025). Cinnamon-induced contact stomatitis: A retrospective study of 74 cases and literature review. Oral Diseases, odi.70081. https://doi.org/10.1111/odi.70081

Powered by WPeMatico

Keto diet linked to reduced depression symptoms in college students: Study

 A new study shows an association between at least 10 weeks of following a well-formulated ketogenic diet and a roughly 70% decrease in depression symptoms among a small group of college students.

Beyond the reduction in self-reported and clinician rated depression, the students’ global well-being increased nearly three-fold and their performance improved on several cognitive tasks. All but one participant also lost weight.

The 16 students who completed the pilot trial were receiving medication, counseling, or both for major depressive disorder before beginning the keto diet. The findings suggest achieving nutritional ketosis through diet is a feasible adjunctive therapy for depression and pave the way for a larger clinical trial, researchers say.

The pilot study did not have a non-keto control group for comparison. Previous research has suggested medications and counseling reduce depressive symptoms by about 50% in a similar time period.

“So many people are suffering right now, so it’s rewarding to potentially bring forward a solution,” said Jeff Volek, PhD, lead author of the study and a professor of human sciences at The Ohio State University. “There is more science yet to do, but because there is evidence of a benefit, expanding accessibility to a well-formulated ketogenic diet as an augmentation to treatment for depression is something to think about.”

The study is published in the journal Translational Psychiatry.

Volek’s lab teamed with Ohio State mental health experts to design and complete the trial with young adults studying at the university.

Stress, anxiety and depression are the No. 1 impediment to academic performance for U.S. college students, said co-author Ryan Patel, DO, a psychiatrist in Ohio State’s Office of Student Life Counseling and Consultation Service: About 40% of college students report depression symptoms, and about half of them are receiving treatment of some kind.

“We have a treatment gap in that we have more students suffering from mental health concerns than can feasibly receive professional treatment,” Patel said. “There is a need for finding ways of helping students on a large scale. And nutrition is one way we can do that.”

Twenty-four students were enrolled in the trial and 16 students – 10 women and six men with an average age of 24 – completed the entire study.

Participants received extensive education on the keto diet, consisting of fewer than 50 grams of carbs per day combined with higher fat and moderate protein intake. The keto diet converts fat into ketones used by cells in the body and brain as an alternative to glucose, and is designed to put the body in a state of nutritional ketosis, when it has greater access to ketones as both fuel and a signaling molecule.

“It was very important to make sure participants knew what they were getting themselves into,” said Drew Decker, MS, first author of the study and a graduate student in Volek’s lab. “And a big part of increasing chances for adherence to the diet was talking to each individual about what they like and don’t like to eat so we could tailor some suggestions for how they could structure their diet.”

The team also provided 10 complete starter meals, offered consistent advice and snacks for the first half of the trial, and communicated throughout the study with participants through a private app. The students were advised to eat when they were hungry and finish eating when they were full, and not to worry about calories.

At baseline and over the course of 10 to 12 weeks, the students reported depressive symptoms using the Patient Health Questionnaire-9 (PHQ-09), the standard instrument to measure the severity of depression in clinical settings, and completed the World Health Organization-Five Well-Being Index (WHO-5). They also took a series of cognitive tests assessing episodic and working memory, processing speed, executive function, and attention and inhibitory control.

Co-author Jennifer Cheavens, PhD, professor of clinical psychology at Ohio State, oversaw clinical assessments of participants before and throughout the trial.

“One of the things we really wanted to make sure of is that we were providing a treatment for people who met the diagnostic criteria for having major depressive disorder,” Cheavens said. “Each participant had about a 2 1/2-hour interview at the beginning, and then weekly assessments of their symptoms.”

Students were also screened to ensure that they did not have any contraindications to a ketogenic diet, such as Body Mass Index under 20, eating disorders, pregnancy or high alcohol consumption.

Results included:

• Participants achieved ketosis, based on a measure of ketone values in their blood, 73% of the time – an indication of good adherence to the diet.

• Self-reported depression scores decreased 37% by week two and reached 69% of improvement at week 10-12. The range of symptom severity varied, but nobody’s symptoms worsened.

• Clinician-rated assessments of depression at week six and week 10-12 decreased by 59% and 71%, respectively.

• By week two, perceived ratings of global wellness had increased two-fold, which improved to nearly three-fold at the end of the intervention.

• As a group, participants lost an average of 11 pounds and their body fat decreased by 2.4% – with most exceeding the clinically significant drop of 5% weight loss.

• As a group, participants’ performance improved on cognitive tasks assessing episodic memory, processing speed and executive function.

• No significant changes in cholesterol or triglycerides were found.

Patel, who met with the students throughout the trial, said the magnitude of the reduction in depressive symptoms linked to the keto diet was notable.

“The average effect size for medications and counseling after 12 weeks is about 50%, and we saw a substantially greater result,” he said. “That is an impressive finding, that across the board, in this real-world setting, everybody got better, and across the board, our participants did not need more treatment or emergency intervention.”

For over two decades, Volek has been studying therapeutic applications of ketosis for conditions such as heart disease and cancer as well as athletic performance and soldier health and resilience.

“The idea is that the ketogenic diet is working through a variety of potentially different mechanisms – there’s a whole range of physiological metabolic adaptations to the diet that could overlap with some of the pathophysiology of depression,” Volek said.

The team collected a range of biological data on changing levels of proteins related to inflammation and brain function in this pilot that may help inform a future study examining potential mechanisms behind the diet’s effects.

“We haven’t teased out those mechanisms here because this is a proof-of-concept study for an adjunctive therapy,” Volek said. “This is one of the first really well-controlled studies and it has limitations, but the results encourage us to want to keep pursuing it.”

Reference:

Decker, D.D., Patel, R., Cheavens, J. et al. A pilot study examining a ketogenic diet as an adjunct therapy in college students with major depressive disorder. Transl Psychiatry 15, 322 (2025). https://doi.org/10.1038/s41398-025-03544-8

Powered by WPeMatico

People on Ozempic who eat to regulate emotions less likely to lose weight, research reveals

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes—helping stabilize blood glucose and lose weight, which contributes to diabetes complications. But not everyone benefits equally.

Powered by WPeMatico

Age-related Eye Diseases Increase Risk of Comorbid CHD and Depression, reveals study

Researchers have discovered in a new study that patients with age-related eye diseases (AREDs) have a significantly increased risk of simultaneously developing coronary heart disease (CHD) and depression as compared to either of the conditions alone. The research established that patients with AREDs, such as age-related macular degeneration, glaucoma, cataract, and diabetes-related eye diseases (DRED), need to undergo extensive screening for CHD and depression comorbidity as a component of chronic disease care. The study was published in the journal of Psychology Research and Behavior Management by He X. and colleagues.

The study was performed using UK Biobank data, with baseline measurements taken between March 2006 and December 2010, and follow-up to July 2021. There were 116,501 participants who were CHD- and depression-free at baseline. During a median follow-up of 11.82 years (interquartile range: 11.51–13.11), investigators examined the incidence of CHD, depression, and comorbidity. Incident cases were established through hospitalization data and self-reporting. Multivariable Cox proportional hazard regression analyses were used to evaluate the risk association of AREDs with health events.

Results

  • During the study duration, 7,750 (6.65%) developed CHD, 3,682 (3.16%) developed depression, and 741 (0.64%) developed both comorbidities together.

  • After controlling for confounding variables, people with AREDs had a 10% higher risk of developing CHD (hazard ratio [HR] 1.10, 95% CI: 1.03–1.17), a 28% higher risk of developing depression (HR 1.28, 95% CI: 1.16–1.42), and a 37% higher risk of developing both conditions as comorbidity (HR 1.37, 95% CI: 1.12–1.67).

  • Subsequent analysis revealed that those with cataract were specifically at risk, having a 57% increased hazard of comorbidity (HR 1.57, 95% CI: 1.23–2.03) and a 26% increased hazard of depression (HR 1.26, 95% CI: 1.10–1.43).

  • Additionally, diabetic eye diseases were found to have an increased hazard of 33% for new CHD (HR 1.33, 95% CI: 1.13–1.56).

  • These results suggest that not all AREDs are equally associated, but as a whole, their presence enhances susceptibility to both cardiovascular and mental disorders.

This research proved that ARED individuals were more likely to co-develop CHD and depression simultaneously than either condition individually. Cataract was highly related to comorbidity and depression, whereas DRED was highly related to CHD risk. These results emphasize the necessity of employing multidisciplinary methods in treating patients with ARED and underscore the significance of early screening and prevention in minimizing long-term disease burden.

Reference:

He, X., Li, C., Wang, Y., Du, Z., Jiang, J., Zhang, W., … Yang, X. (2025). Association of Age-Related Eye Diseases with Comorbidity of Coronary Heart Disease and Depression in a Population-Based Cohort Study. Psychology Research and Behavior Management, 18, 1931–1942. https://doi.org/10.2147/PRBM.S533879

Powered by WPeMatico

Tirzepatide and Thiazide Use in CKD Linked to Risk of Severe Hypercalcemia, Reveals Case Report

USA: Researchers have reported a potential risk of severe hypercalcemia when tirzepatide, a dual GIP and GLP-1 receptor agonist, is used in combination with chronic thiazide diuretics—particularly hydrochlorothiazide (HCTZ)—in patients with pre-existing chronic kidney disease (CKD).  

The finding comes from a new case report published in Endocrinology, Diabetes & Metabolism Case Reports, highlighting a previously unrecognized interaction between these commonly used medications in individuals with type 2 diabetes and other comorbidities.
The case involved a 65-year-old woman with obesity, hypertension, CKD stage 3, and type 2 diabetes, who had been on long-term Losartan/HCTZ therapy. Shortly after receiving her first dose of tirzepatide, she developed symptomatic hypercalcemia, presenting with generalized weakness, altered mental status, fatigue, mild constipation, and increased urination. Laboratory testing revealed a corrected calcium level of 4.58 mmol/L, far exceeding the normal range of 2.12–2.62 mmol/L. Interestingly, parathyroid hormone and vitamin D levels were low, and imaging studies ruled out malignancy or other structural causes, pointing to a drug-related etiology.
Management focused on immediate cessation of both tirzepatide and HCTZ, aggressive intravenous hydration, and short-term calcitonin therapy. The patient responded rapidly, with calcium levels returning to normal by the fourth day of hospitalization. Subsequent follow-up confirmed sustained normocalcemia, demonstrating that timely recognition and intervention can prevent long-term complications.
The report raises concerns about a potential pharmacological interaction between tirzepatide and thiazide diuretics, which may be particularly significant in patients with impaired renal function. Thiazides are known to reduce urinary calcium excretion, increasing the risk of hypercalcemia, while tirzepatide may influence calcium metabolism through effects on bone turnover and parathyroid hormone regulation. Although GLP-1 and GIP receptor agonists are generally not associated with significant disturbances in calcium homeostasis, the case highlights that their combination with chronic thiazide therapy could produce severe electrolyte abnormalities.
The authors emphasize the need for clinicians to maintain vigilance when prescribing tirzepatide to patients on thiazide diuretics, especially those with CKD. Baseline and early follow-up monitoring of serum calcium—within one to two weeks of initiating therapy—is strongly recommended to detect abnormalities before they become symptomatic. Recognizing hypercalcemia promptly is critical, as symptoms can be nonspecific, including confusion, weakness, fatigue, polyuria, and constipation.
While a single case cannot establish causality, it highlights the importance of pharmacovigilance as newer GLP-1 and GIP agonists are increasingly incorporated into diabetes and obesity management. The report calls for further studies to explore the mechanisms behind tirzepatide’s effect on calcium metabolism and to better understand potential drug-drug interactions with thiazide diuretics. With careful monitoring, clinicians can mitigate risks and ensure safe use of these increasingly popular therapeutic agents in vulnerable populations.
Reference:
Nduma B, Malapati SN, Vibhuti V. A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use. Endocrinol Diabetes Metab Case Rep. 2025;2025(3):e250067. Published 2025 Sep 5. doi:10.1530/EDM-25-0067

Powered by WPeMatico

Vancomycin Linked to Higher AKI Risk in ICU Patients: Study

A recent target trial emulation study found that vancomycin use in ICU patients is associated with a higher risk of acute kidney injury compared to alternatives such as clindamycin and linezolid, highlighting the importance of following established prevention strategies. The study was published in Pharmacoepidemiology & Drug Safety journal by Izak A. and colleagues.

The analysis was founded on a hypothetical trial simulation employing routinely collected data from 15 Dutch ICUs over the period between 2010 and 2019. The data of 1,809 ICU admissions were analyzed. Patients who underwent vancomycin were compared with those that were treated with other minimally nephrotoxic antibiotics, such as clindamycin, linezolid, teicoplanin, meropenem, cefazolin, and daptomycin.

Acute kidney injury was classified based on the KDIGO serum creatinine criteria. To adjust for confounding and selection bias, inverse probability of treatment and censoring weighting was used in the analysis. Risk estimates were reported at 2 days and 14 days after the start of antibiotics, taking into consideration the 24–48 hour delay between renal function worsening and detection by SCr.

Results

  • The analysis revealed that vancomycin use was not related to a higher risk of AKI in the first 2 days.

  • In 2 days, AKI risk was 0.10 (95% CI 0.06–0.12) among vancomycin users compared with 0.10 (95% CI 0.08–0.11) among alternative antibiotic users, with a risk difference of 0.00 (95% CI −0.03–0.03).

  • By day 14, a definitive difference had emerged. The risk adjusted for AKI was 0.28 (95% CI 0.21–0.34) for vancomycin versus 0.17 (95% CI 0.14–0.20) for the alternative antibiotic.

  • This represented a risk difference of 0.11 (95% CI 0.04–0.19), meaning that vancomycin was linked to a much increased risk of kidney damage over time.

The research concluded that vancomycin was associated with a higher risk of acute kidney injury in comparison to other antibiotics when administered for 14 days in ICU patients. The authors suggest strict compliance with vancomycin-induced AKI preventive protocols and that less nephrotoxic alternatives should be considered where possible in order to protect renal function in critically ill patients.

Reference:

Yasrebi-de Kom, I. A. R., Jager, K. J., Stel, V. S., Chesnaye, N. C., Abu-Hanna, A., de Keizer, N. F., de Lange, D. W., Dongelmans, D. A., Klopotowska, J. E., Cinà, G., & the RESCUE Study Group. (2025). Vancomycin‐induced acute kidney injury in intensive care patients: A target trial emulation study using multicenter routinely collected data. Pharmacoepidemiology and Drug Safety, 34(9). https://doi.org/10.1002/pds.70205

Powered by WPeMatico

Psoriasis Treatments Show No Impact on Blood Glucose Levels: Study

A new study published in Dermatology just put to rest the idea that biologics or methotrexate might double as anti-diabetes medications for people with psoriasis. Researchers tracked HbA1c levels in 386 psoriasis patients over the course of a year—those treated with TNF-α inhibitors (like adalimumab and infliximab), IL-17 inhibitors (brodalumab, ixekizumab, secukinumab), IL-12/23 inhibitor (ustekinumab), IL-23 inhibitors (guselkumab, risankizumab), and methotrexate. Across all treatment groups, HbA1c values stayed essentially unchanged. A tiny increase seen with secukinumab was deemed not clinically significant. Even when the analysis focused only on patients with higher initial HbA1c (36–47 mmol/mol), treatment had zero impact.

Why does this matter? People with psoriasis generally run a higher risk of developing type-2 diabetes—likely tied to chronic inflammation. It’s tempting to hope that anti-inflammatory biologics or methotrexate could pull double duty by improving glucose metabolism. But this study’s data suggest otherwise: these effective skin-clearing treatments don’t seem to nudge blood sugar.

That doesn’t mean biologics aren’t valuable—they still work wonders for managing skin symptoms and overall inflammation. But for diabetics, or psoriasis patients concerned about long-term metabolic risks, it’s important to know these drugs don’t appear to offer glycemic protection.

For clinicians, this means continuing to monitor HbA1c routinely, just like in any other patient, and pushing for proven metabolic strategies—diet, exercise, medications when needed—rather than assuming psoriasis treatment alone will move the needle.

Reference:
Bukhari, M. F., Schwarz, C. W., Zachariae, C. O. C., Loft, N., & Skov, L. (2025). No change in HbA1c levels during treatment with biologics or methotrexate in patients with psoriasis. Dermatology. https://doi.org/10.1159/000547591 [API]

Keywords: psoriasis, biologic therapy, methotrexate, HbA1c, glucose metabolism, antidiabetic effect, Dermatology journal

Powered by WPeMatico

Over 14,000 B.Pharm, D.Pharm Seats Filled in MP, Vacancies Push Second Round

Bhopal: In a major development for pharmacy aspirants, a total of 14,128 seats in B.Pharmacy and D.Pharmacy courses have been allotted during the first round of counselling in Madhya Pradesh. Despite the large number of allotments, more than 5,200 seats still remain vacant, paving the way for the second round of admissions.

As per official figures, 10,413 seats in B.Pharmacy and 3,715 seats in D.Pharmacy have been allotted across institutes in the state. The counselling process involved 179 B.Pharmacy institutes and 194 D.Pharmacy institutes.

Candidates who have been allotted seats are required to report to their respective institutes and complete the document verification process by September 18. The second round of counselling will be conducted online between September 19 and October 3 to fill the remaining vacant seats.

Dainik Bhaskar reports that the allotment and admission schedule has been carried out under state guidelines to ensure transparency in the process. Officials highlighted that the vacancies from the first round will be carried forward to the second round to maximise enrolments.

Powered by WPeMatico